{"nctId":"NCT02984384","briefTitle":"PREVENTion of Clot in Orthopaedic Trauma","startDateStruct":{"date":"2017-04-24","type":"ACTUAL"},"conditions":["Blood Clot","Trauma"],"count":12424,"armGroups":[{"label":"Low Molecular Weight Heparin (LMWH)-Enoxaparin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Low Molecular Weight Heparin (LMWH)"]},{"label":"Acetylsalicylic acid (ASA)-Aspirin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Acetylsalicylic acid"]}],"interventions":[{"name":"Acetylsalicylic acid","otherNames":["Aspirin"]},{"name":"Low Molecular Weight Heparin (LMWH)","otherNames":["Enoxaparin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have a planned operative or non-operative pelvis or acetabular fracture, or any operative extremity fracture proximal to the metatarsals or carpals.\n* Patients at increased risk of blood clot(s) from their orthopaedic injury(ies) and will receive prophylactic blood thinner regimen per standard of care.\n* Patients 18 years or older.\n\nExclusion Criteria:\n\n* Patients who present to the hospital more than 48 hours post injury\n* Patients who received more than 2 doses of LMWH or aspirin for initial VTE prophylaxis\n* Patients on long term blood thinners (other than low-dose aspirin or platelet inhibitors such as Plavix or Aggrenox)\n* Patients who have had a VTE within the last 6 months\n* Patients on therapeutic (as opposed to prophylactic) blood thinners for an acute issue at the time of admission\n* Patients who have a newly diagnosed indication for therapeutic blood thinners (for example vascular injury) that will require therapeutic anticoagulation for more than one week\n* Patients who cannot receive either of the study medications due to an allergy (history of heparin induced thrombocytopenia, allergy to aspirin, or NSAIDs) or other medical contraindication to blood thinners\n* Patients who are on higher dose aspirin (\\>81 mg once a day or higher) for medical reasons or who will be treated with higher dose aspirin\n* Patients with underlying chronic clotting disorders (i.e. Factor V Leiden, hyperhomocysteinemia, Protein C and S deficiency) that require full dose anticoagulation or are a contraindication to venous thromboembolism chemoprophylaxis\n* Patients with end stage renal disease or impaired creatinine clearance \\<30 ml/min at time of randomization(note: creatinine clearance does not need to be documented if prescribing physician would order medication without test as SOC)\n* Pregnant or lactating patients\n* Prisoners\n* Patients who do not speak either English or Spanish\n* Patients who are likely to have severe problems maintaining follow-up\n* Patients, based upon the clinical judgment of the treating clinician, NOT equally suited for treatment with either aspirin or low-molecular-weight heparin\n* Patients may be excluded for other reasons at the discretion of the treating physician; the reason for exclusion must be documented on the screening form\n* Patients who have a known COVID-19 diagnosis prior to fracture treatment or within 3 months of the index fracture","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With All-cause Mortality","description":"Death from any cause","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cause-specific Death","description":"Cause specific death. Some participants are reported twice if reason for death met more than one category.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-fatal Pulmonary Embolism","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Deep Vein Thrombosis","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]}]},{"type":"SECONDARY","title":"Bleeding Complication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"869","spread":null},{"groupId":"OG001","value":"834","spread":null}]}]}]},{"type":"SECONDARY","title":"Wound Complication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Deep Surgical Site Infection","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":260,"n":6110},"commonTop":["Bleeding complication","Wound complication"]}}}